Prior Authorization Program
|
|
|
- Nickolas Pitts
- 5 years ago
- Views:
Transcription
1 Prescription Drug List January 2011 Prior Authorization Program The prior authorization program helps us offer broad prescription drug coverage and promotes safe, clinically appropriate drug usage. Under the prior authorization program, certain drugs require approval. Your physician may call our Pharmacy Prior Authorization Department to request a medical necessity review. If you have any questions or concerns, please contact Member Services at the number listed on your ID card. This list is for informational purposes only and is subject to change. To confirm coverage, please contact your plan administrator or call the customer service number on your health plan ID card. Anemia Aranesp Darbepoetin Alfa Epogen Epoetin Alfa Procrit Epoetin Alfa Arthritis/Pain Conditions* Arthrotec* Diclofenac Sodium /Misoprostol (Generic products in this category Celebrex* Celecoxib do not require Prior Authorization) Flector* Diclofenac transdermal patch Mobic* Meloxicam Pennsaid* Diclofenac sodium topical solution Ponstel* Mefenamic Acid Prevacid Naprapac* Naproxen/Lansoprazole Voltaren gel* Diclofenac topical gel Arthritis/Related Inflammatory Conditions Actemra Tocilizumab Enbrel Etanercept Humira Adalimumab Kineret Anakinra Orencia Abatacept Rituxan Rituximab Simponi Golimumab Asthma Xolair Omalizumab Cancer Afinitor Everolimus Avastin Bevacizumab Firmagon Degarelix Gleevec Imatinib Mesylate Herceptin Trastuzumab Mylotarg Gemtuzumab Ozogamicin Nexavar Sorafenib Tosylate Novantrone Mitoxantrone Revlimid Lenalidomide Rituxan Rituximab Sprycel Dasatinib Sutent Sunitinib Malate Tarceva Erlotinib Tasigna Nilotinib Thalomid Thalidomide Treanda Bendamustine Hcl Tykerb Lapatinib Ditosylate Votrient Pazopanib Zolinza Vorinostat d 12/10 1 mycignaforhealth.com
2 Chemokine Receptor Mozobil Plerixafor CAPS Arcalyst Rilonacept Ilaris Canakinumab Crohn s Disease Cimzia Certolizumab Pegol Humira Crohn s Starter Pack Adalimumab Tysabri Natalizumab Dystonia and Spasticity Botox Botulinum Toxin A Dysport Abobotulinumtoxin A Myobloc Botulinum Toxin B Enzyme Deficiency Elaprase Idursulfase Growth Deficiency Genotropin Humatrope Increlex Mecasermin Rinfabate Norditropin Nutropin Nutropin AQ Nutropin Depot Omnitrope Saizen Serostim Tev-Tropin Growth Hormone Receptor Antagonists Somavert Pegvisomant Heartburn/Ulcer* Dexilant* Dexlansoprazole (Generic products in this category Prevacid* Lansoprazole do not require Prior Authorization) Prilosec* Omeprazole Prilosec Susp.* Omeprazole Protonix* Pantoprazole Zegerid* Omeprazole/sodium bicarbonate Hemophilia Advate Alphanate Alphanate/VWF Antihemophilic Factor/von Willebrand Factor complex (Human) AlphaNine SD Autoplex T Anti-inhibitor Coagulant Complex Bebulin VH BeneFix Factor IX Complex (Recombinant) Feiba VH Anti-inhibitor Coagulant Complex Helixate FS Hemofil M Humate-P Koate-DVI Kogenate FS Monarc-M Monoclate-P Mononine Factor IX (Purified/Human) NovoSeven Factor VIIa (Recombinant) Profilnine SD Proplex T Recombinate Hemophilia (continued) ReFacto 2
3 Wilate Antihemophilic Factor VIII Von Willibrand (Human) Xyntha Hepatitis Infergen Interferon Alfacon-1 Pegasys Peginterferon Alfa-2a Peg-Intron Peginterferon Alfa-2b Hyperlipidemia (high cholesterol)* Altoprev* Lovastatin, extended-release (Generic products in this category Crestor* Rosuvastatin do not require Prior Authorization) Livalo* Pitavastatin Mevacor* Lovastatin Pravachol* Pravastatin Zocor* Simvastatin Hypertension* Atacand* Candesartan/HCTZ Angiotensin II Avalide* Irbesartan/HCTZ Antagonists (ARBs) Azor* Olmesartan/Amlodipine Avapro* Irbesartan Benicar* Olmesartan Benicar HCT* Olmesartan/HCTZ Cozaar* Losartan Diovan* Valsartan Diovan HCT* Valsartan/HCTZ Exforge* Valsartan/Amlodipine Hyzaar* Losartan/HCTZ Micardis* Telmisartan Micardis HCT* Telmisartan/HCTZ Tekturna* Aliskiren Tekturna HCT* Aliskiren/HCTZ Teveten* Eprosartan Teveten HCT* Eprosartan/HCTZ Twynsta* Telmisartan/Amlodipine Valturna* Aliskiren/Valsartan Immune System Deficiency Carimune NF Flebogamma Gammagard Liquid Gammagard S/D Gamunex Hizentra Immune Globulin SQ Iveegam EN Octagam Polygam S/D Privigen Vivaglobin Immune Globulin SQ Infertility Bravelle Urofollitropin Cetrotide Cetrorelix Acetate Clomid Clomiphene Citrate Fertinex Urofollitropin Follistim AQ Follitropin Beta, Recombinant Ganirelix Acetate** Ganirelix Acetate Ganirelix Acetate/Follistim Ganirelix Acetate/Follitropin Beta Gonal-F Follitropin Alpha, Recombinant Luveris Lutropin Alfa Menopur Menotropin 3
4 Infertility (continued) Novarel Ovidrel Pregnyl Profasi Repronex Menotropin Serophene Clomiphene Citrate Insomnia* Ambien* Zolpidem, immediate release (Generic products in this category Ambien CR* Zolpidem do not require Prior Authorization) Edluar* Zolpidem SR Lunesta* Eszopiclone Rozerem* Ramelteon Sonata* Zaleplon ITP Nplate Romiplostim Promacta Eltrombopag Multiple Sclerosis Ampyra Dalfampridine Avonex Admin Pack Interferon Beta-1a Betaseron Interferon Beta-1b Copaxone Glatiramer Acetate Extavia Interferon Beta-1b Novantrone Mitoxantrone Rebif Interferon Beta-1a/Albumin Tysabri Natalizumab Narcolepsy Nuvigil Armodafinil Provigil Modafinil OB/Gyn 17-hydroxy-progesterone Hydroxyprogesterone Caproate USP PKU Kuvan Sapropterin Psoriasis Amevive Alefacept Enbrel Etanercept Humira Adalimumab Stelara Ustekinumab Pulmonary Hypertension Adcirca Tadalafil Flolan Epoprostenol Letairis Ambrisentan Remodulin Treprostinil Revatio, injection Sildenafil Citrate Tracleer Bosentan Ventavis Iloprost Respiratory Syncytial Virus (RSV) Synagis Palivizumab 4
5 - Therapeutic category Therapeutic drugs Actinic Keratosis Zyclara Imiquimod Angioedema Cinryze C1 Esterase inhibitor Kalbitor Ecallantide Diabetes Victoza Liraglutide Mucopolysaccharidosis VI Nagalazyme Galsulfase (Maroteaux-Lamy Syndrome) Neuropathic Pain Qutenza Topical Patch Capsaicin 8% topical patch Postherpetic Neuralgia (PHN) Pompe Disease Myozyme Alglucosidase alfa * Drug is part of the Step Therapy program only. Step Therapy is a prior authorization program designed for you and your doctor to take one step at a time when choosing your medication. It works to help you find the most affordable medication appropriate for your condition. ** Ganirelix Acetate injection was formerly called Antagon. This list is for informational purposes only and is subject to change. To confirm coverage, please contact Member Services at the phone number listed on your ID card. CIGNA and the Tree of Life logo are registered service marks of CIGNA Intellectual Property, Inc., licensed for use by CIGNA Corporation and its operating subsidiaries. All products and services are provided exclusively by such operating subsidiaries, including Connecticut General Life Insurance Company and CIGNA Health and Life Insurance Company, and not by CIGNA Corporation d 12/ CIGNA. mycignaforhealth.com 5
RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)
INFECTIOUS DISEASE ACTIMMUNE INTERFERON GAMMA 1B J9216 ADVATE RAHF PFM ONCOLOGY ORAL AFINITOR EVEROLIMUS J7527 INFECTIOUS DISEASE ALFERON N INTERFERON ALFA N3 J9215 ALPHANATE VWF J7186 ALPHANINE SD J7193
TRICARE Uniform Formulary. Pre-Authorization Requirements
TRICARE Uniform Formulary Pre-Authorization Requirements The Department of Defense (DoD) requires pre-authorization on select medications. These medications are on the DoD s pre-authorization list because
Aetna Better Health. Specialty Drug Program
Aetna Better Health is managed through CVS Health Specialty Pharmacy. The Specialty pharmacies fill prescriptions and ship drugs for complex medical conditions, including multiple sclerosis, rheumatoid
PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION
Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate
Prescription Drug Benefit Rider
Prescription Drug Benefit Rider Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your
BCBS AZ ADV PLUS * CLASSIC * PREMIER For use with members associated with the BHN Network Prior Authorization List 2015
Prior Authorization List 2015 Participating providers are responsible to furnish or arrange health care services with other participating healthcare facilities or providers. Prior authorization requests
Prescription Drug Benefit Rider V
Prescription Drug Benefit Rider V Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your
PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION
Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 25 March 2010
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 25 March 2010 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical
List of Designated High-Cost Drugs
List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at
MedStar Medicare Choice Pharmacy Services
Pharmacy Services 1 MedStar Medicare Choice Pharmacy Services Table of Contents At a Glance..page 2 Pharmacy Policies..page 4 Medicare Choice Pharmacy Programs..page 6 Where to Obtain Prescriptions..page
Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015
J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,
Pharmacy and Medical Guideline Updates
STAT Bulletin PO Box 15013 Albany, New York 12212 August 2, 2010 Volume 8: Issue 19 To: All PCPs and Specialists Contracts Affected: All Lines of Business Pharmacy and ical Guideline Updates As a result
STAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business
STAT Bulletin November 28, 2011 Volume 9: Issue 27 To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat
SELF-ADMINISTERED MEDICATIONS LIST
SELF-ADMINISTERED MEDICATIONS LIST Table of Contents Page Last Updated: January 23, 2019 INSTRUCTIONS FOR USE... 1 APPLICABLE CODES... 1 Related Commercial Policy LIST HISTORY/REVISION INFORMATION... 5
Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List
Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Code Drug Name Effective and/or Term Date J0129 Injection, abatacept (Orencia ), 10 mg J0178 Injection, aflibercept (Eylea
Descriptor Brand Name. Alprostadil, Caverject, Edex, Prostin VR Pediatric. Calcimar, Miacalcin
Self-Administered Drug Exclusion List R2 This article from Medicare A News, Issue 2106 dated January 23, 2013 and Medicare B News, Issue 283 dated January 23, 2013 is being revised to add Acthar ACTH gel
STAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business
STAT Bulletin November 28, 2011 Volume 17: Issue 34 To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat
Prescription Drug Benefit Rider
Prescription Drug Benefit Rider Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your
Three-Tier Prescription Drug Benefits Rider
Three-Tier Prescription Drug Benefits Rider Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions
FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES J Code Prior Authorizations & Required Clinical Information 2011 (Updated 3/14/11)
FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES J Code Prior Authorizations & Required Clinical Information 2011 (Updated 3/14/11) Brand Generic J Code Covered Uses Required Medical Information and
Pharmacy Services Request Types
FOR DRUG REQUESTS, ONLY-- * NOTE: Only those drugs administered by a healthcare provider and billed medically would be entered via CareAffiliate. * Oral drugs would not be administered by a healthcare
Positively Affecting the Lives of Members Each and Every Day. Volume 14 May Specialty Drug News
Positively Affecting the Lives of Members Each and Every Day LDI Volume 14 May 2008 Specialty Drug News 2008 Medications to Watch 1. Respiratory syncytial virus (RSV) Numax (motavizumab) Respiratory syncytial
Three-Tier Prescription Drug Benefit Rider A
Three-Tier Prescription Drug Benefit Rider A Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions
UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008
UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008 Promoting high quality, cost effective drug therapy throughout the Military Health System UF Decisions, May 07 Class FY05 rank, total $
RxBlue 2010 ST Criteria
RxBlue 2010 ST Criteria ANTIDEPRESSANTS - SARAFEM... 10 FLUOXETINE HCL... 10 SARAFEM... 10 SELFEMRA... 10 ANTIDEPRESSANTS- SSRI, SNRI... 11 CELEXA... 11 CITALOPRAM... 11 CYMBALTA... 11 EFFEXOR XR... 11
Generics. Lead with. P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m
Lead with Generics P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m WWW.BCBSLA.COM 04HQ3972 5/09 Blue Cross and Blue Shield of Louisiana incorporated as Louisiana Health Service & Indemnity
Injectable Drugs Requiring Pre-Service Approval
Abatacept Orencia J0129, 10 mg 1500 FL LCD- L29051 1) For patients with rheumatoid arthritis with failure, intolerance or contraindications to methotrexate. Limit dosing to 40 mg Q 2 weeks. 2) For patients
Percent Brand Name Generic Name Strength How Supplied NDC from AWP/SWP Adcetris. Amprya dalfampridine 10 mg 60 count bottle
Department of General Services Procurement Division Contract # 01-14- 65-57 Pharmaceutical Acquisitions Section Exhibit G-1 April 30, 2015 Walgreens Specialty Pharmacy LLC, Products Pricing Crescent Healthcare,
Exclusion Reasons Presumption of Long- Term Non-Acute Administration C9399 Unclassified Drugs or
Noridian Healthcare Solutions, LLC Jurisdiction F Part B Self-Administered Drug (SAD) Exclusion List (A53033); Effective 8/7/2017 The following medications are considered self-administered and are not
METABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST
PRIOR AUTHORIZATION LIST (SUBJECT TO CHANGE) MEDICATION THERAPEUTIC CATEGORY MODULE ACTEMRA INFLAMMATORY CONDITIONS ACTEMRA ADCIRCA PULMONARY HYPERTENSION PDE-5 INHIBITORS FOR PAH ADDYI SEXUAL DISORDERS
2010 Drugs Requiring Prior Authorization
2010 Drugs Requiring Prior Authorization Drugs Covered Uses Exclusion Criteria Actemra (tocilizumab) Adcirca (tadalafil) Alfa Interferons - Alferon N - Infergen - PEG-Intron - PEG-Intron Redipen - Pegasys
Generics. Lead with. Prescription Step Therapy Program
Lead with Generics Prescription Step Therapy Program WWW.BCBSLA.COM 04HQ3972 R11/10 Blue Cross and Blue Shield of Louisiana incorporated as Louisiana Health Service & Indemnity Company GENERIC DRUGS: A
Medication Prior Authorization Form
Section I Member Information Name (Last, First, Middle Initial) Date of Birth WEA Trust Subscriber Number Diagnosis Page 2 1. MEDICATION 2. STRENGTH 3. DIRECTIONS 4. QUANTITY FEIBA NF NovoSeven RT HEMOFIL
Original Policy Date
MP 5.01.17 Specialty Drugs Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/ Date Local policy Last updated/12:2013 Return to Medical Policy Index
SPECIALTY PHARMACY Master Clinical Drug List
Abraxane J9264 Provider ONCOLOGY None NO Actemra J3262 Provider ARTHRITIS PA - all YES Acthar HP Gel J0800 Prov/Self Med/Pharm ENDOCRINE/METABOLIC PA - all YES Adagen J2504 Provider ENZYME DISORDERS None
2018 BCN Advantage Prior Authorization Criteria Last updated: April, 2018
Abstral Actemra Adcirca Adempas Aliqopa Afinitor Afinitor- Disperz Alecensa Alunbrig Amitiza Amitriptyline Ampyra Anadrol-50 Androgel Androderm Aralast NP Aranesp Arcalyst Armodafinil Aubagio Avonex Bavencio
2018 BCN Advantage Prior Authorization Criteria Last updated: November, 2017
Abstral Actemra Adcirca Adempas Afinitor Afinitor- Disperz Alecensa Alunbrig Amitiza Amitriptyline Ampyra Anadrol-50 Androgel Androderm Aralast NP Aranesp Arcalyst Armodafinil Aubagio Avonex Bavencio Beleodaq
Angiotensin II Receptor Antagonists (ARBs), Renin Inhibitors, and Combinations Step Therapy Program Summary
OBJECTIVE The intent of the Angiotensin II Receptor Antagonists (ARBs), Renin Inhibitors, and Combinations Step Therapy (ST) program is to encourage use of cost-effective generic products - ACEIs, ACEI
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Antihypertensive Medications Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Antihypertensive Medications Prime Therapeutics will review Prior Authorization
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS. February 201 0
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS I. CONVENING February 201 0 The Department of Defense (DoD) Pharmacy and Therapeutics (P&T) Committee convened at 0800 hours on
LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT
LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT The following medications may be covered under your medical benefit if they are provided to you in your doctor s office or outpatient infusion
J-Code Trade Name Drug Name Required Medical Information
FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES Updated: 10/31/2017 J-Code Prior Authorizations & Required Clinical Information Medicaid, Child Health Plus, HealthierLife, Metal-Level J-Code Trade
Injections Requiring Prior Authorization
At VIVA Health, we strive to keep our provider network informed of any changes. Most of you may currently obtain prior authorizations for administered injections. Below is a list of injection, infusion,
Utilization Management
Abraxane Abraxane Actemra (IV) Inflammatory Conditions PA/Step Actemra (SQ) Inflammatory Conditions PA/Step Acthar HP Miscellaneous CNS Disorders PA Actimmune NF Adcetris Adcirca Adempas Advate (all forms)
Immune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
Medicare Shared Savings Program Accountable Care Organization (ACO) Measures Deep Dive Series
Medicare Shared Savings Program Accountable Care Organization (ACO) Measures Deep Dive Series At Risk Population: Measure 33 Coronary Artery Disease (CAD-7): Angiotensin-Converting Enzyme (ACE) Inhibitor
Step Therapy Criteria
ADCIRCA ADCIRCA Coverage will be provided if the member has filled a prescription for sildenafil (at least a 30 day supply within the past 365 ) ELIDEL 76-F ELIDEL Coverage will be provided if the member
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document - Oral Drugs requiring prior authorization: the list of drugs requiring prior
STEP THERAPY ALGORITHMS PUP Select Formulary
The Step Therapy drug will be dispensed if the drug has been dispensed within 120 days of current fill or if alternative (Step 1) drugs have been used first. If the member s prescription claim fails the
MDwise Self-Administered Codes for Medical
The following codes are associated with medications that can be self-administered by the patient or a caregiver. As a result, MDwise will transfer coverage of these self-administered medications exclusively
Specialty Overview by Prior Authorization Approval or Denial 2nd Quarter 2016
Specialty Overview by Prior Authorization Approval or 2nd Quarter 2016 3961 DERMATOLOGY Humira RHEUMATOID ARTHRITIS Approval Approved from 04/13/2016 thru 04/13/2018 3961 DERMATOLOGY Stelara PSORIASIS
Specialty conditions overview
Specialty conditions overview Prevalence and cost Click on the vials to learn more about these specialty conditions. 1. Approximate annual AWP cost per patient of top utilized drugs for UHC calendar year
of our members each and
s p e c i a l t y d r u g n e w s Positively affecting the lives of our members each and every day Efalizumab (Raptiva ) Withdrawn from US Market On April 9, 2009 Genentech, Inc. announced that it is undergoing
Quarterly Pharmacy Formulary Change Notice
Quarterly Pharmacy Formulary Change Notice Summary of Change: The formulary changes listed in the table below were reviewed and approved at our December 18, 2014 Value Assessment Committee (VAC) meeting.
Drug Therapy Guidelines
Drug Therapy Guidelines Applicable Injectable Fertility Medications: Bravelle, Cetrotide, Follistim AQ, Ganirelix, Gonal-F, human chorionic gonadotropin, leuprolide, Menopur, Novarel, Ovidrel, Pregnyl,
Center for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
Drug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit Effective: 8/15/18 Pharmacy- Formulary 1 x Next Review: 6/18 Pharmacy- Formulary 2 x Date of Origin: 7/00 Injectable Fertility Medications: Bravelle,
Pulmonary Hypertension Weight Loss Skin Conditions. Skin Conditions Multiple Sclerosis Endocrine Disorder. Endocrine Disorder.
Prior Authorization PricewaterhouseCoopers The following medications may require prior authorization prior to dispensing at a participating retail pharmacy or through the Express Scripts Pharmacy home
New Billing Guidelines for Home Infusion, Enteral and Parenteral Therapies Home Infusion Fee Schedule Effective July 1, 2009
STAT Bulletin PO Box 80 Buffalo, New York 14240-0080 May 12, 2009 Volume 15:Issue 18 To: All Home Health Care and Home Infusion Therapy Providers Contracts Effected: All Lines of Business New Billing Guidelines
Brand Generic J-Code 1 Billable. Exclusion Criteria. Information and Criteria. Unit
Affinity Health Plan Department Of Pharmacy (Medicaid, Child Health Plus, Family Health Plus, Medicare Part B) **Medications Requiring Authorization under Medical Benefit** Click Here For Medication Authorization
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Oral Drugs requiring prior authorization: the list of drugs requiring prior
Drug Name Generic Name J-Code Unclassified Drugs in excess of $10,000
Unclassified Drugs in excess of $10,000 J3490 Unclassified Biologics in excess of $10,000 J3590 Revenue Codes in excess of $10,000 R250 - R259 ABRAXANE paclitaxel protein-bound J9264 & J9267 ACTEMRA tocilizumab
Prior January 2016 Authorization What Is Prior Authorization? What Happens at a Retail Pharmacy? Please Note: Which Medications Are Included?
Prior January 2016 Authorization What Is Prior Authorization? It s a quality and safety program that promotes the proper use of certain medications. If your doctor prescribes a medication that is included
CHICAGO REGIONAL COUNCIL OF CARPENTERS WELFARE FUND RETIREE PRESCRIPTION DRUG BENEFITS October 2013
CHICAGO REGIONAL COUNCIL OF CARPENTERS WELFARE FUND RETIREE PRESCRIPTION DRUG BENEFITS October 2013 How to Use the Prescription Drug Program The Chicago Regional Council of Carpenters Welfare Fund has
after reconstitution No Yes Refrigerate; do Not freeze. Discard unused portions; do Not save for further Immune Deficiencies & Related
Store at room temp. Protect from bright light. Freezing or refrigerating do not adversely affect the stability of intact vials. Different standards apply Abraxane Oncology- Injectable IV No No Yes after
March 2017 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
Actemra. Products Affected ACTEMRA INTRAVENOUS. Covered Uses
Actemra ACTEMRA INTRAVENOUS All medically accepted indications not otherwise excluded plus patients already started on tocilizumab for a covered use. Castleman's disease. Still's disease. Concurrent use
DISCLOSURES. Online A. Infectious Complications of Monoclonal Antibody Therapies 6/22/2012. Cytokine blocking. Lymphocyte depleting.
Online A Infectious Complications of Monoclonal Antibody Therapies Steven M. Holland, M.D. Off-Label Usage None DISCLOSURES Financial Relationships with Relevant Commercial Interests None Resolution: N/A
ART Drugs. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.02 Subject: ART Drugs Page: 1 of 7 Last Review Date: December 3, 2015 ART Drugs Description Bravelle
RHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
ART Drugs. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.02 Subject: ART Drugs Page: 1 of 7 Last Review Date: September 15, 2017 ART Drugs Description Bravelle
PA Category Name Code(s) Additional Notes ABA 0364T 0365T 0366T 0367T 0373T 0374T H G0396. Applied Behavioral Analysis stage 3*
ABA BEHAVIORAL HEALTH CHEMICAL DEPENDENCY Applied Behavioral Analysis stage 3* Neuropsychological Testing Chemical Dependency/Substance Abuse* (MA Only) 0364T 0365T 0366T 0367T 0373T 0374T H2020 96116
Mountain Health Trust/WV Health Bridge
Mountain Health Trust/WV Health Bridge Preferred Drug List (PDL) The West Virginia Preferred Drug List (PDL) is a list of medications recommended to BMS by the West Virginia Medicaid Pharmaceutical and
Formulary Changes. One mission: you TABLE A. FORMULARY CHANGES 7/1/2018: Commercial 3-Tier Formulary. Commercial 4-Tier Formulary
One mission: you Changes July 1, 2018 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for
UPMC for You Pharmacy and Therapeutics Committee Meeting July 27, 2010 meeting
1. Call to order: The meeting was called to order at 7:10 a.m. UPMC for You Pharmacy and Therapeutics Committee Meeting July 27, 2010 meeting 2. Review of the minutes: The minutes of the April 6, 2010
II. Angiotensin Receptor Blockers (ARBs) Drug Class Review
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE DOD BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32 C.F.R. 199.21,
Section I contains changes to the Highmark Select/Choice Formulary.
March 2008 1 st Quarter Update: Highmark Drug Formulary Enclosed is the 1 st Quarter 2008 update to the Highmark Drug Formulary and pharmaceutical management procedures. The Formulary and pharmaceutical
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy
2019 Step Therapy (ST) Criteria
2019 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
Clinical Policy: Angiotesin II Receptor Blockers and Renin Inhibitors Reference Number: CP.HNMC.15 Effective Date: Last Review Date: 08.
Clinical Policy: Reference Number: CP.HNMC.15 Effective Date: 11.16.16 Last Review Date: 08.17 Revision Log Line of Business: Medicaid Medi-Cal See Important Reminder at the end of this policy for important
ACTEMRA. Cigna Medicare Rx (PDP) 2014 Cigna Medicare Rx Secure-Xtra Plan (PDP) Formulary. Products Affected Actemra. Prior Authorization Criteria
Cigna Medicare Rx (PDP) Medicare Part D Prescription Drug Plans 2014 Cigna Medicare Rx Secure-Xtra Plan (PDP) Formulary Prior Authorization ACTEMRA Products Affected Actemra PA Details Age Other Authorization
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
Prior Authorization April 2018
Prior Authorization April 2018 Please Note: Not all benefit plans include prior authorization. Check your plan materials to see if this information applies to you. What Is Prior Authorization? It s a quality
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Diovan, Diovan HCT, Exforge, Exforge HCT, Teveten) Reference Number: CP.HNMC.16 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important
Cerner Bulletin Providers Issued: October 2, 2014
Alert Warfarin Ordered without INR CPOE, Nursing and Pharmacy 10/13/14 S B A R Prescribers currently do NOT get a warning if warfarin is actively ordered and there has not been an INR result in the past
INJECTABLE MEDICINES. Resources, Links or Additional Information. J Code Brand Names Generic names Prior Authorization or Restrictions
J9190 5-FU fluorouracil None. J0401 ABILIFY MAINTENA aripiprazole i.v. J9264 ABRAXANE paclitaxel protein bound J3262 ACTEMRA IV tocilizumab Yes, through Navitus. Restricted to (in at least consultation
LDI integrated pharmacy services
8 ARRANON CARIMUNE NF Immunodeficiency 8-MOP Psoriasis ARZERRA CAYSTON Cystic Fibrosis A ASTAGRAF XL Antirejection CERDELGA Gaucher's Disease abacavir ATRIPLA CEREZYME Gaucher's Disease abacavir/lamivudine/
Supplementary Materials for
immunology.sciencemag.org/cgi/content/full/1/2/eaah3539/dc1 Supplementary Materials for IL-1 is an innate immune sensor of microbial proteolysis Christopher N. LaRock,* Jordan Todd, Doris L. LaRock, Joshua
Annual Review of Antihypertensives - Fiscal Year 2009
Annual Review of Antihypertensives - Fiscal Year 2009 Oklahoma HealthCare Authority April 2010 Current Prior Authorization Criteria There are 7 categories of antihypertensive medications currently included
ASEBP and ARTA TARP Drugs and Reference Price by Categories
ASEBP Pantoprazole Sodium 40 mg (generic) $0.2016 ASEBP Dexlansoprazole 30 mg Dexlansoprazole 60 mg Esomeprazole 10 mg Esomeprazole 20 mg Esomeprazole 40 mg Lansoprazole 15 mg Lansoprazole 30 mg Omeprazole
ACAMPROSATE (CAMPRAL)
ACAMPROSATE (CAMPRAL) ACAMPROSATE CALCIUM Creatinine clearance less than 30 PAGE 1 LAST UPDATED 06/2016 ADALIMUMAB (HUMIRA) HUMIRA, HUMIRA PEDIATRIC CROHN'S, HUMIRA PEN, HUMIRA PEN CROHN'S-UC-HS, HUMIRA
Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
Information is based on the NCQA 2016 Technical Specifications.
s Provider Tips for Optimizing HEDIS Results Mount Carmel Health Partners wants to help improve your Quality Ratings. These tip sheets offer the key aspects of a specific HEDIS measure as well as useful
Cimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
Self-Injected Medications and Disposal Recommendations
Actimmune (interferon gamma 1b) Apokyn (apomorphine hydrochloride) Arixtra (fondaparinux) Avonex (interferon beta 1a) Betaseron (interferon beta 1b) Copaxone (glatiramer acetate) Edex (alprostadil) InterMune
Guardian Coverage Management
What is Coverage Management? Coverage Management is a review of certain prescribed drugs, or drug quantities to verify that they are covered according to plan rules. Plan rules are based on FDA approved